IntroductionProlyl 3-hydroxylases (P3H) are crucial enzymes in collagen biosynthesis and are known to be involved in a variety of physiological processes. However, their specific roles in cancer progression, modulation of the tumor microenvironment (TME), and impact on patient prognosis remain areas that require further investigation.MethodsThe investigation involved a comprehensive analysis of expression profiles and clinical data obtained from the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases. This included the assessment of genetic variation, gene expression, and the prognostic significance of P3H family genes. P3H scores were calculated using various databases and R-based tools, followed by correlation analyses with the TME, immune cell infiltration, drug sensitivity and immunotherapy.Variations in P3H gene expression patterns were observed across different tumor types and prognoses, suggesting that most genes within the family were risk factors, especially P3H1 and P3H4. The P3H score was associated with immune infiltration and drug resistance. Notably, individuals with elevated expression of P3H2, P3H3, and CRTAP exhibited higher resistance to multiple anti-tumor drugs.ResultsP3H family proteins play diverse roles in cancer progression, significantly impacting patient prognosis and the effectiveness of immunotherapy.ConclusionsThe P3H score, identified as a potential biomarker for evaluating TME, holds promise in guiding precision medicine strategies.

中文翻译：

---

P3H家族在癌症中的作用：对预后、肿瘤微环境和药物敏感性的影响

简介脯氨酰 3-羟化酶 (P3H) 是胶原蛋白生物合成中的关键酶，已知参与多种生理过程。然而，它们在癌症进展、肿瘤微环境（TME）调节以及对患者预后的影响中的具体作用仍然需要进一步研究。方法研究涉及对从基因型-组织表达（ GTEx）和癌症基因组图谱（TCGA）数据库。这包括评估遗传变异、基因表达和 P3H 家族基因的预后意义。使用各种数据库和基于 R 的工具计算 P3H 评分，然后进行与 TME、免疫细胞浸润、药物敏感性和免疫治疗的相关性分析。在不同肿瘤类型和预后中观察到 P3H 基因表达模式的变化，这表明大多数基因家庭是危险因素，尤其是P3H1和P3H4。 P3H评分与免疫浸润和耐药性相关。值得注意的是，P3H2、P3H3和CRTAP表达升高的个体对多种抗肿瘤药物表现出更高的耐药性。结果P3H家族蛋白在癌症进展中发挥不同作用，显着影响患者预后和免疫治疗的有效性。结论P3H评分被确定为用于评估 TME 的潜在生物标志物，有望指导精准医疗策略。